Castrate-resistant prostate cancer: postdocetaxel management

about

Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.Prostate cancer vaccines in combination with additional treatment modalities.

P2860

Q33416977-385D1C25-75C8-497C-8B6E-CA790976035B Q38212571-5D202313-C8F5-4306-B2C7-05283EEF106D

P2860

Castrate-resistant prostate cancer: postdocetaxel management

Item

http://www.wikidata.org/entity/Q38076273

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Castrate-resistant prostate cancer: postdocetaxel management

@en

type

Item

label

Castrate-resistant prostate cancer: postdocetaxel management

@en

prefLabel

Castrate-resistant prostate cancer: postdocetaxel management

@en

P1476

Castrate-resistant prostate cancer: postdocetaxel management

@en

P2093

Evan Y Yu

http://www.w3.org/2001/XMLSchema#string

Song Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

Abiraterone and increased survival in metastatic prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

P304

201-207

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MOU.0B013E32835E2253

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23344012

http://www.w3.org/2001/XMLSchema#string

P932

4486479

http://www.w3.org/2001/XMLSchema#string

Castrate-resistant prostate cancer: postdocetaxel management

about

P2860

P2860

Castrate-resistant prostate cancer: postdocetaxel management

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932